Regenerative Medicine Catalyst Grants 2026
Supports translational research to accelerate clinical development of stem cell therapies, biomaterials, analytics, and cell-based regenerative medicine.
Funder: Novo Nordisk Foundation
Due Dates: September 1, 2026 (Phase I concept note) | December 17, 2026 (Phase II full application)
Funding Amounts: Up to DKK 5 million (standard, Nordic only) or DKK 10 million (collaborative, with international co-applicant) per grant; total program budget DKK 100 million; up to 3 years per project.
Summary: Supports translational research to advance regenerative medicine, focusing on stem cell therapies, biomaterials, analytics, and clinical development.
Key Information: Two-stage application: concept note, then full proposal by invitation only.
Description
The Novo Nordisk Foundation’s Regenerative Medicine Catalyst Grants 2026 provide catalytic funding for translational research projects addressing major challenges in regenerative medicine. The program’s primary aim is to accelerate the development and clinical translation of stem cell-based therapies, innovative biomaterials, robust analytical methods, and scalable clinical development strategies. Projects must have a strong applied and translational focus, clear goals, and the potential for significant impact on the regenerative medicine field, particularly in the Nordic region but with encouragement for international collaboration.
